Drug Profile

Research programme: fibroblast growth factor receptor inhibitors - Cogent Biosciences

Alternative Names: FGFR2 inhibitors - Cogent Biosciences

Latest Information Update: 28 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cogent Biosciences
Class Antineoplastics; Small molecules
Mechanism of Action Type-2 fibroblast growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer

Most Recent Events

28 Apr 2026 No recent reports of development identified for preclinical development in Cancer in USA
06 Aug 2024 Cogent Biosciences plans a phase I trial for Cancer in the second half of 2024.
02 Nov 2023 Pharmacodynamics data from a preclinical studies in Cancer released by Cogent Biosciences

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com